US Army AMC RFPP: Rapid Access to Products in Development (RAPID)

Notice ID: W911SR249RAPID

Related Notice: W911SR-24-S-RAPID

DESCRIPTION/OBJECTIVE OF THE PROJECT. The Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense, Enabling Biotechnologies (JPEOCBRND-EB), develops, manufactures and delivers safe and effective Medical Countermeasures (MCMs) for preparedness, prevention, protection, response, and recovery from CBRN threats. Today’s chemical and biological threat landscape is diverse, dynamic, and regionally distinct. Agile and flexible defense systems are required to provide Combatant Commands (CCMDs) and other stakeholders throughout the Chemical and Biological Defense Program (CBDP) with actionable information regarding MCM availability at the speed of relevance.

The Rapid Access to Products in Development (RAPID) program is an integrated defense system composed of both physical MCM storage and fielding capabilities and a readily accessible information warehouse and sharing system (the RAPID data management solution or data system).  The RAPID data system will identify and incorporate diverse data sets, curate and categorize the data, enable contextualized analysis of the integrated body of information, and provide a diverse set of stakeholders with actionable information necessary to make complex, resource-driven, and mission-focused decisions about continued development and/or fielding of MCMs.   The RAPID System is not intended to be used for bio surveillance (e.g., tracking outputs from fielded ChemBio detection platforms). Physical storage and fielding of MCMs are outside the scope of …

Prototype Project Objective. Complex data and information related to CBRN MCMs will be stored and organized in the RAPID Data system so that it is intuitively accessible by a variety of stakeholders and end users. The Data system is intended to provide actionable information to assist (1) JPEO- and CBDP level decision makers when determining portfolio investment strategies and/or rapid response adjustments based on changing circumstances and (2) CCMD-level decision makers when evaluating a RAPID MCM for potential administration or for potential rapid deployment to enable fielding to US warfighters.  The RAPID Data system will organize developmental MCMs using a Tier-based schema (See Table 1), with Tier 1 encompassing products early in development and Tier 3 designating MCMs with successfully completed Phase 1 clinical studies and an inventory of available doses.  When queried by CBRN threat type, the data system needs to return, at a minimum, a list of potential MCMs along with their characteristics, tier data packages, availability, and developmental stage. A dashboard view will allow end users to easily view MCM coverage across individual and families of biological and chemical threats. Multiple user types are envisioned, including but not …

JPEO-CBRND-EB is seeking an interactive data management solution that enables (including but not limited to):

• Flexible integration of multiple data types from multiple sources without loss of context or meaning.
• Semi or fully automated identification and retrieval of new relevant information in accessible data sources as close to real time as possible …

Project Objectives.  The primary objective of this effort is to develop a RAPID data management solution to enable stakeholders to make data-driven decisions about fielding and/or accelerating development of MCMs. The targeted objectives include:

1. The RAPID data management solution will be composed of chemical and biological weapons threat and relevant medical countermeasure product data, including products that are in development.
2. The data management solution must be accessible to a broad array of stakeholders using USG systems, including NIPR, SIPR, and JWICS. The contractor must provide appropriately cleared personnel and be able to support implementation and maintenance on those systems.
3. The Offeror will be responsible for creating and incorporating current information relevant for development of novel MCMs against DoD-relevant chemical and biological threats (e.g., cell receptors, pathogenicity, LD50, endemic range, animal models, etc.). This generally does not include intelligence community analysis of threat space, though links to those analyses may be …

The anticipated Period of Performance for this effort is up to 1 year from date of award. Specific dates to be negotiated.  It is anticipated that the primary place of performance will be the contractors’ facilities, however this aspect can be negotiated as part of each Offerors’ submission.

Read more here.

🔊 Listen to Story